EXO Biologics
Stijn Van Rompay is an accomplished executive in the pharmaceutical and financial sectors, currently serving as CEO and reference shareholder of Hyloris Pharmaceuticals, a Belgian specialty biopharma company, since 2014. Van Rompay has extensive experience as a board member and reference shareholder at PE Group, which specializes in private equity investments. Additional roles include Chairman of EXO Biologics and member of the board at IMCYSE, a firm focused on novel immune therapies. Van Rompay previously held leadership positions at Alter Pharma, Uteron Pharma, and Docpharma, overseeing the development and commercialization of pharmaceuticals in various therapeutic areas. An alumnus of the University of Antwerp with a Master's degree in Economics, Stijn Van Rompay has demonstrated a strong commitment to addressing unmet medical needs through innovative solutions.
This person is not in any teams
EXO Biologics
EXO Biologics is a Belgian clinical-stage biotechnology company focusing on researching and developing novel sub-cellular therapeutic candidates based on exosomes. Exo Biologics mission is to provide affordable and accessible exosomes therapies to patients with unmet medical needs. Exo Biologics has strong partnerships and influential networks for collaborating and researching new medical treatments, including research centers, public universities, and private partners.